First Author: I.Alarcón Valero SPAIN
Co Author(s): D. Vilaplana i Blanch V. Poposki O. Martínez-Giralt X. Acebes Roldan 0 0 0 0 0 0 0 0 0
Back to previous
To show the efficacy of PDT to improve VA in patients with Central Serous Chorioretinopathy in any of its clinical forms. • To show the efficacy of PDT to treat complications of Central Serous Chorioretinopathy.
Ophalmology Department in Parc de Salut Mar
CLASSIC CSC PDT can be useful to treat CSC specially when the patient suffers more than one episode with the same focal leak in the fundus. • Case 1: Male 35 years old. 3 episodes of acute CSC in five months. VA 20/30 12 months after PDT, VA 20/20 and no more episodes of CSC and closure of the focal leak. CHRONIC CSC Photodynamic therapy is the first line treatment in this kind of CSC. The purpose of the treatment is to solve the chronic RD and avoid new recurrences. CNV SECONDARY TO CSC PDT was the first line treatment for CNV but it has been replaced by anti-VEGF drugs. Despite this, PDT is still a good option to treat CNV secondary to CSC itself or combined with anti-VEGF drugs • Case 3: Female, 58 years old. Chronic CSC with CNV. VA 20/100. 12 months after PDT, VA 20/40 and closure of CNV with no more recurrences
• In classic CSC the discussion is focused in deciding if treatment is mandatory or not. • If treatment is decided laser photocoagulation, PDT or anti-VEGF drugs are the options. • In chronic CSC, PDT or anti-VEGF drugs are the options. • In both cases PDT achieves better long term results in terms of visual acuity. • In CNV secondary to CSC you can decide to use PDT, anti-VEGF drugs or a combination of both.
• Despite we are now in the Anti-VEGF era, Photodynamic Therapy is still a useful and valuable treatment in Central Serous Chorioretinopathy. • It shows good long term results in terms of visual acuity and avoids recurrences with very few complications.